This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Merck ROMK potassium channel blocker, MK-8153, is a backup development candidate to MK-7145, whose development as a diuretic was terminated…
molecule
2 years ago ●
1 min read
The Janssen RORgt inhibitor, JNJ-61803534, is an oral clinical candidate that was well-tolerated in humans up to 200 mg and demonstrated…
molecule
2 years ago ●
2 mins read
The Merck LMP7 inhibitor, M3258, is an orally available, selective, and reversible inhibitor of the immunoproteasome proteolytic subunit, LMP7. In contrast…
molecule
2 years ago ●
1 min read
The BMS CCR2 inhibitor, BMS-753426, is a potent, oral follow-up molecule to prior clinical candidate, BMS-741672. A small change from a…
molecule
2 years ago ●
1 min read
The Lutris-Parma topical BRAF inhibitor, LUT014, is intended to treat rash caused by EGFR inhibitors. Rash is a significant and common…
molecule
2 years ago ●
1 min read
The Galapagos S1PR2 antagonist GLPG2938 is a preclinical candidate intended for the treatment of idiopathic pulmonary fibrosis (IPF). Though several S1PR1 modulators…
molecule
2 years ago ●
1 min read
Load More
